PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31637414-1 2020 BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). Isocitrates 129-139 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 172-180 32003035-1 2020 PURPOSE: To generate a preclinical model of isocitrate dehydrogenase (IDH) mutant gliomas from glioma patients and design a MRS method to test the compatibility of 2-hydroxyglutarate (2HG) production between the preclinical model and patients. Isocitrates 44-54 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 70-73 31833548-5 2020 To clarify the mechanisms that mutant isocitrate dehydrogenase (IDH) affect the intraoperative fluorescence, in Vitro experiments using genetically engineered glioma cells harboring mutant IDH1 were performed. Isocitrates 38-48 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 64-67 31637414-1 2020 BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). Isocitrates 129-139 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 172-176 31637414-1 2020 BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) WHO grade II or III that present with a) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or b) gain of chromosome 7 combined with loss of chromosome 10, and/or c) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). Isocitrates 129-139 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 172-178 31586149-1 2020 Mutations in isocitrate dehydrogenase 1 (IDH1) are found in 6% of AML patients. Isocitrates 13-23 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 41-45 32025842-5 2020 Isocitrate dehydrogenase inhibitors (IDH) constitute another therapeutic class with DNA methylation effects in AML. Isocitrates 0-10 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 37-40 32027343-1 2020 Importance: Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively. Isocitrates 128-138 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 166-169 31969485-1 2020 Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas. Isocitrates 45-55 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 75-81 31969485-1 2020 Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas. Isocitrates 45-55 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 125-131 31963507-14 2020 In line with this finding, the expression levels for TSPO and AIF1 were also significantly higher in (isocitrate-dehydrogenase wild-type) IDHWT compared to IDH mutant (IDHMUT) GBM. Isocitrates 102-112 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 138-141 31935911-2 2020 Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers, including conventional and dedifferentiated chondrosarcomas. Isocitrates 13-23 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 47-53 31908598-9 2020 An increased success rate of implantation in gliomas with wild type isocitrate dehydrogenase (IDH) and high Ki67 expression was observed compared to gliomas with mutant IDH and low Ki67 expression. Isocitrates 68-78 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 94-97 32055803-1 2020 Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to alpha-ketoglutarate (alphaKG). Isocitrates 88-98 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 34-38 31714193-0 2020 MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. Isocitrates 20-30 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 46-49 31726354-8 2020 A trend showed that tumours associated with poorer outcomes (recurrent tumours and Isocitrate Dehydrogenase - IDH wildtype) displayed higher viability on chip than tumours linked with improved outcomes (low-grade gliomas, IDH mutants and primary tumours). Isocitrates 83-93 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 110-113 31929772-3 2020 For example, D-2-hydroxyglutarate, generated due to the activity of mutated mitochondrial isocitrate dehydrogenase (IDH), has been implicated in the pathogenesis of leukemia. Isocitrates 90-100 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 116-119 31907132-1 2019 Objective To investigate the clinical value of serum tumor marker isocitrate dehydrogenase 1(IDH1)in the diagnosis of lung cancer. Isocitrates 66-76 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 93-97 31888244-2 2019 IDH1wt converts isocitrate to alpha-ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+), whereas IDH1R132H uses alpha-ketoglutarate and NADPH to generate the oncometabolite 2-hydroxyglutarate (2-HG). Isocitrates 16-26 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 31921684-1 2019 Objectives: In the present study, we aimed to determine the candidate genes that may function as biomarkers to further distinguish patients with isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM), which are heterogeneous with respect to clinical outcomes. Isocitrates 145-155 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 171-174 31921378-1 2019 This case report aimed to review the bone marrow features of patients with acute myeloid leukemia (AML) treated with isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors. Isocitrates 117-127 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 147-153 31810230-1 2019 Chondrosarcomas are chemo- and radiotherapy resistant and frequently harbor mutations in isocitrate dehydrogenase (IDH1 or IDH2), causing increased levels of D-2-hydroxyglutarate (D-2-HG). Isocitrates 89-99 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 115-119 31795195-2 2019 KRAS/NRAS mutations are common in ICC tumours and 6-32% of patients also have isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene mutations associated with metabolic changes. Isocitrates 78-88 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 112-116 31632056-0 2019 Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City. Isocitrates 30-40 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 62-66 31742037-12 2019 Mutations in gene encoding isocitrate dehydrogenase 1 and 2 (IDH 1&2) occur in some enchondromas and spindle cell hemangiomas. Isocitrates 27-37 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 61-66 31660152-1 2019 Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) in the tricarboxylic acid (TCA) cycle. Isocitrates 77-87 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-24 31660152-1 2019 Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) in the tricarboxylic acid (TCA) cycle. Isocitrates 77-87 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 26-29 31632056-2 2019 A variety of mutations have been identified at the molecular level, such as those in the IDH1/2 gene, which causes a gain of function of the isocitrate dehydrogenase enzyme, generating high levels of the (R)-2-hydroxyglutarate oncometabolite, which competitively inhibits dioxygenase enzymes. Isocitrates 141-151 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 89-95